Paul Mellett Net Worth

The estimated Net Worth of Paul J Mellett is at least $11.9 Milione dollars as of 5 December 2023. Mr. Mellett owns over 2,412 units of Enanta Pharmaceuticals Inc stock worth over $1,126,330 and over the last 11 years he sold ENTA stock worth over $9,270,168. In addition, he makes $1,531,560 as Chief Financial Officer e Senior Vice President - Finance & Administration at Enanta Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mellett ENTA stock SEC Form 4 insiders trading

Paul has made over 34 trades of the Enanta Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 2,412 units of ENTA stock worth $23,228 on 5 December 2023.

The largest trade he's ever made was exercising 92,132 units of Enanta Pharmaceuticals Inc stock on 12 March 2014 worth over $67,256. On average, Paul trades about 6,975 units every 60 days since 2013. As of 5 December 2023 he still owns at least 93,549 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Mr. Mellett stock trades at the bottom of the page.

Paul Mellett biography

Paul J. Mellett Jr. serves as Chief Financial Officer, Senior Vice President - Finance & Administration of the Company. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics, Inc., a publicly-held biotechnology company. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989. Mr. Mellett received a B.S. in Business Administration from Boston College in 1977.

What is the salary of Paul Mellett?

As the Chief Financial Officer e Senior Vice President - Finance & Administration of Enanta Pharmaceuticals Inc, the total compensation of Paul Mellett at Enanta Pharmaceuticals Inc is $1,531,560. There are 3 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.

How old is Paul Mellett?

Paul Mellett is 64, he's been the Chief Financial Officer e Senior Vice President - Finance & Administration of Enanta Pharmaceuticals Inc since 2003. There are 7 older and 8 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.

What's Paul Mellett's mailing address?

Paul's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb... e Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.

What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Complete history of Mr. Mellett stock trades at Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jay Luly,
  President, Chief Executive Officer, Director
• Yat Sun Or,
  Senior Vice President - Research & Development, Chief Scientific Officer
• Nathalie Adda,
  Senior Vice President and Chief Medical Officer
• Paul Mellett,
  Chief Financial Officer, Senior Vice President - Finance & Administration
• Nathaniel Gardiner,
  Senior Vice President, General Counsel
• Dr. Jay R. Luly,
  Pres, CEO & Director
• Dr. Yat Sun Or,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Nathalie Adda,
  Sr. VP & Chief Medical Officer
• Nathaniel S. Gardiner J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Paul J. Mellett Jr.,
  Sr. VP of Fin. & Admin. and CFO
• Bruce Carter,
  Independent Non-Executive Chairman of the Board
• Terry Vance,
  Independent Director
• George Golumbeski,
  Independent Director
• Lesley Russell,
  Independent Director
• Kristine Peterson,
  Independent Director
• Mark Foletta,
  Independent Director
• Carol Miceli,
  Director, Investor Relations
• Brendan Luu,
  Sr. VP of Bus. Devel.
• Tara Lynn Kieffer Ph.D.,
  Sr. VP of New Product Strategy & Devel.
• Jennifer Viera,
  Sr. Director of Investor Relations & Corp. Communications
• Ernst Guenter Afting,
  Director
• Tim Ocain,
  Senior Vice President
• Stephen Jr. Buckley,
  Director
• V Life Science Ventures Gmb...,
  
• V Life Science Ventures Gmb...,
  
• Helmut Schuhsler,
  Director
• David Poorvin,
  Director
• Capital Granite, L.P.M Rna ...,
  
• Marc E. Goldberg,
  Director
• Gregory L. Verdine,
  Director
• & Co Ltd Shionogi,
  10% owner
• Yujiro S Hata,
  Director
• Brendan Luu,
  Chief Business Officer
• Scott T. Rottinghaus,
  Chief Medical Officer
• Tara Lynn Kieffer,
  Chief Product Strategy Officer
• Matthew Paul Kowalsky,
  Chief Legal Officer